9594.Se
The company operates in the healthcare sector, providing pharmaceutical products and related services, and generates revenue primarily through the sale of its pharmaceutical offerings.
Business. The company operates in the healthcare sector, providing pharmaceutical products and related services, and generates revenue primarily through the sale of its pharmaceutical offerings.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, providing pharmaceutical products and related services, and generates revenue primarily through the sale of its pharmaceutical offerings.
The company maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.37, indicating a moderate reliance on debt financing. Its liquidity position is characterized as medium, with a current ratio of 1.52, suggesting it has sufficient short-term assets to cover its short-term liabilities, though not in excess. The company's free cash flow of 2,976,400 indicates a modest ability to fund operations and growth without external financing.
Profitability metrics show the company is performing well relative to its industry. The return on equity of 21.5% and return on assets of 11.8% are strong indicators of efficient use of equity and assets to generate profit. These figures suggest the company is outperforming the typical industry median for these metrics, which are key indicators of financial health and operational efficiency.
The company's revenue is concentrated in a single segment, as disclosed in its financial reporting, with no geographic diversification provided in the available data. This lack of segment and geographic diversification may expose the company to higher concentration risk, as its performance is tied to a single business line and potentially a single market.
Looking ahead, the company is expected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. Historical revenue data shows a consistent performance, and the outlook for the current and next fiscal years is neutral, with no projected revenue growth or decline.
The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests potential liquidity constraints, but the low dilution risk indicates that the company is not expected to issue additional shares in the near term, preserving shareholder value.
Recent financial filings and transcripts do not indicate any material events or changes in the company's operations or strategy. The company continues to operate within its disclosed business model, with no significant new initiatives or strategic shifts reported in the latest available documents.
- The company maintains a strong return on equity and return on assets, indicating efficient use of capital and assets.
- The company's liquidity position is moderate, with a current ratio of 1.52, suggesting it can meet short-term obligations but with limited buffer.
- The company's revenue is concentrated in a single segment, which may increase its exposure to market-specific risks.
- The company is expected to maintain a stable revenue performance in the next fiscal year, with no significant growth or decline projected.
- The company's risk profile is characterized by medium liquidity risk and low dilution risk, suggesting a relatively stable financial position.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 9594.SE Market data — financials · 2026-05-27